[go: up one dir, main page]

MX2019000849A - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents

Gel intestinal de levodopa y carbidopa y metodos de uso.

Info

Publication number
MX2019000849A
MX2019000849A MX2019000849A MX2019000849A MX2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A
Authority
MX
Mexico
Prior art keywords
methods
levodopa
intestinal gel
carbidopa
carbidopa intestinal
Prior art date
Application number
MX2019000849A
Other languages
English (en)
Inventor
M Lipari John
Huang Ye
Deac Alexandru
Ruggles Alexander
Yu Tun Thin
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2019000849A publication Critical patent/MX2019000849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona (a) una composición farmacéutica que comprende un agente activo de levodopa y un agente activo de carbidopa y (b) métodos para tratar la enfermedad de Parkinson y afecciones asociadas que comprenden administrar la composición farmacéutica a un sujeto con enfermedad de Parkinson.
MX2019000849A 2016-07-20 2017-07-20 Gel intestinal de levodopa y carbidopa y metodos de uso. MX2019000849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20
PCT/US2017/043103 WO2018017850A1 (en) 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (1)

Publication Number Publication Date
MX2019000849A true MX2019000849A (es) 2019-09-13

Family

ID=59506369

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000849A MX2019000849A (es) 2016-07-20 2017-07-20 Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2022014577A MX2022014577A (es) 2016-07-20 2019-01-18 Gel intestinal de levodopa y carbidopa y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014577A MX2022014577A (es) 2016-07-20 2019-01-18 Gel intestinal de levodopa y carbidopa y metodos de uso.

Country Status (9)

Country Link
US (4) US20180021280A1 (es)
EP (1) EP3487479A1 (es)
JP (3) JP2019523249A (es)
CN (1) CN109715139A (es)
AU (2) AU2017299710A1 (es)
BR (1) BR112019001082A2 (es)
CA (1) CA3031254A1 (es)
MX (2) MX2019000849A (es)
WO (1) WO2018017850A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
EP3758754A1 (en) 2018-03-02 2021-01-06 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
EP4023292A4 (en) * 2019-08-30 2023-09-06 TERUMO Kabushiki Kaisha Injection formulation
EP4616878A1 (en) * 2024-03-15 2025-09-17 Cosmo Technologies Ltd. Cannula for rectal administration of an enema and compositions for use therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
CN1968680A (zh) * 2003-10-31 2007-05-23 阿尔扎公司 促进加巴喷丁和普加巴林的吸收的组合物和剂型
US20080051459A1 (en) * 2006-05-31 2008-02-28 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
DE102006034346B4 (de) * 2006-07-25 2008-11-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung
US20150182688A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
SE538425C2 (en) * 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
US10071069B2 (en) * 2014-09-04 2018-09-11 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
BR112019001082A2 (pt) 2019-04-30
EP3487479A1 (en) 2019-05-29
CA3031254A1 (en) 2018-01-25
AU2023203340A1 (en) 2023-06-22
CN109715139A (zh) 2019-05-03
JP2022166217A (ja) 2022-11-01
US20260014108A1 (en) 2026-01-15
US20180021280A1 (en) 2018-01-25
US20230129413A1 (en) 2023-04-27
WO2018017850A1 (en) 2018-01-25
JP2019523249A (ja) 2019-08-22
US20210059968A1 (en) 2021-03-04
AU2017299710A1 (en) 2019-01-31
JP2025000924A (ja) 2025-01-07
MX2022014577A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2024001203A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2018000021A (es) Composiciones multifasicas.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
AR106313A1 (es) Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones